- Home
- CNTA vs DYN Comparison
CNTA vs DYN Comparison
Compare CNTA & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNTA
- DYN
- Stock Information
- Founded
- CNTA 2020
- DYN 1984
- Country
- CNTA United Kingdom
- DYN United States
- Employees
- CNTA N/A
- DYN N/A
- Industry
- CNTA Biotechnology: Pharmaceutical Preparations
- DYN Medicinal Chemicals and Botanical Products
- Sector
- CNTA Health Care
- DYN Health Care
- Exchange
- CNTA Nasdaq
- DYN Nasdaq
- Market Cap
- CNTA 1.6B
- DYN 1.3B
- IPO Year
- CNTA 2021
- DYN 2020
- Fundamental
- Price
- CNTA $13.51
- DYN $11.96
- Analyst Decision
- CNTA Strong Buy
- DYN Strong Buy
- Analyst Count
- CNTA 11
- DYN 12
- Target Price
- CNTA $27.00
- DYN $47.00
- AVG Volume (30 Days)
- CNTA 730.3K
- DYN 2.5M
- Earning Date
- CNTA 05-14-2025
- DYN 05-08-2025
- Dividend Yield
- CNTA N/A
- DYN N/A
- EPS Growth
- CNTA N/A
- DYN N/A
- EPS
- CNTA N/A
- DYN N/A
- Revenue
- CNTA $15,000,000.00
- DYN N/A
- Revenue This Year
- CNTA N/A
- DYN N/A
- Revenue Next Year
- CNTA N/A
- DYN N/A
- P/E Ratio
- CNTA N/A
- DYN N/A
- Revenue Growth
- CNTA 118.88
- DYN N/A
- 52 Week Low
- CNTA $7.90
- DYN $6.36
- 52 Week High
- CNTA $19.09
- DYN $47.45
- Technical
- Relative Strength Index (RSI)
- CNTA 56.37
- DYN 55.03
- Support Level
- CNTA $12.11
- DYN $11.52
- Resistance Level
- CNTA $13.23
- DYN $12.34
- Average True Range (ATR)
- CNTA 0.73
- DYN 0.78
- MACD
- CNTA 0.12
- DYN -0.02
- Stochastic Oscillator
- CNTA 98.13
- DYN 42.47
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.
About DYN Dyne Therapeutics Inc.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.